LLC Redmile Group Acquires Shares in Fate Therapeutics

LLC Redmile Group recently acquired 87,900 shares of Fate Therapeutics, Inc. (NasdaqGM: FATE) on June 12, 2026. The transaction was recorded with no purchase price, and the stock was trading at $2.06 at the time.

What Changed in LLC Redmile Group's Fate Therapeutics Position

This purchase of 87,900 shares by LLC Redmile Group marks a new addition to their holdings in Fate Therapeutics. The transaction was not part of a pre-planned trading program.

Other Institutional Activity in Fate Therapeutics

Other significant institutional movements in Fate Therapeutics include Vanguard Capital Management LLC and Vanguard Portfolio Management LLC, each adding over 4.1 million shares, bringing their totals to approximately 4.2 million and 4.1 million shares, respectively, valued at around $5.03 million and $4.96 million. On the other hand, BlackRock, Inc. reduced its stake by 107,873 shares, ending with approximately 10.1 million shares valued at $12.1 million.

Fate Therapeutics Stock Snapshot

Shares of NasdaqGM:FATE traded near $2.06 recently. Fate Therapeutics has a market cap of about $240.1 million and a forward P/E ratio that isn't meaningful due to its lack of profitability. The stock's 52-week range is between $0.91 and $2.88, with a 50-day moving average of $1.80 and a 200-day moving average of $1.33. The company maintains a solid current ratio of 5.85 and a quick ratio of 5.746, with a debt-to-equity ratio of 42.728.

Recent Earnings

Fate Therapeutics reported revenue of $6.3 million, although it experienced a revenue decline of 20.3%. The company is not currently profitable, with a net margin of 0% and a return on equity of -55.5%. The next earnings report is expected on August 11, 2026.

Insider Buying and Selling at Fate Therapeutics, Inc.

Several insiders, including Shefali Agarwal and Yuan Xu, each bought 87,900 shares of Fate Therapeutics on June 12, 2026. These purchases were not part of any planned trading programs.

Analysts Set New Price Targets

On June 8, 2026, HC Wainwright & Co. reiterated its 'buy' rating on Fate Therapeutics, setting a price target of $7.00. The consensus among analysts is a 'buy' rating, with an average target price of $5.41 based on nine analyst opinions.

About Fate Therapeutics

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. It focuses on developing programmed cellular immunotherapies to treat cancer and immune disorders. The company is working on various product candidates, including FT836 and FT522, aimed at treating different tumor types and B-cell Lymphoma. Fate Therapeutics collaborates with Ono Pharmaceutical for CAR T-cell products targeting solid tumors.

Bottom Line

LLC Redmile Group's recent purchase of Fate Therapeutics shares highlights ongoing interest in the biotechnology firm. Although Fate Therapeutics is not currently profitable, its strategic focus on innovative cancer therapies continues to attract attention. Investors should note that such insider transactions are typically disclosed after they occur, and the information may not reflect current positions.